Clinical and Prognostic Implications of an Immune-Related Risk Model Based on TP53 Status in Lung Adenocarcinoma

Researchers developed a 6-gene immune-related risk model to predict the survival of patients with lung adenocarcinoma (LUAD) in The Cancer Genome Atlas cohort based on TP53 status, and the predictive ability was confirmed in two independent cohorts.